InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2026-02-18 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| 2025-12-11 | Gilbert Cisneros(D-CA31) | house | Sale | $1,001 - $15,000 |
| 2025-08-04 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| 2025-06-04 | Josh Gottheimer(D-NJ05) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Alliance revenues | $9.27B+10.5% | $8.39B+10.6% | $7.58B-11.2% | $8.54B+11.6% | $7.65B |
| Total revenues | $62.58B-1.6% | $63.63B+6.8% | $59.55B-41.1% | $101.17B+24.5% | $81.29B |
| Cost of sales | $16.07B-10.0% | $17.85B-28.5% | $24.95B-27.3% | $34.34B+11.4% | $30.82B |
| Selling, informational and administrative expenses | $13.79B-6.4% | $14.73B-0.3% | $14.77B+8.0% | $13.68B+7.7% | $12.70B |
| Research and development expenses | $10.44B-3.6% | $10.82B+1.3% | $10.68B-6.6% | $11.43B+10.3% | $10.36B |
| Acquired in-process research and development expenses | $1.61B+1393.5% | $108.0M-44.3% | $194.0M-79.6% | $953.0M-72.5% | $3.47B |
| Amortization of intangible assets | $4.87B-7.8% | $5.29B+11.7% | $4.73B+31.1% | $3.61B-2.5% | $3.70B |
| Restructuring charges and certain acquisition-related costs | $1.55B-35.9% | $2.42B-17.8% | $2.94B+114.0% | $1.38B+71.4% | $802.0M |
| Other (income)/deductions––net | $6.72B+53.2% | $4.39B+1876.6% | $222.0M-79.1% | $1.06B+121.8% | -$4.88B |
| Income from continuing operations before provision/(benefit) for taxes on income | $7.52B-6.3% | $8.02B+658.3% | $1.06B-97.0% | $34.73B+42.9% | $24.31B |
| Provision/(benefit) for taxes on income | -$266.0M-850.0% | -$28.0M+97.5% | -$1.11B-133.5% | $3.33B+79.7% | $1.85B |
| Income from continuing operations | $7.79B-3.3% | $8.05B+270.7% | $2.17B-93.1% | $31.40B+39.8% | $22.46B |
| Discontinued operations––net of tax | $25.0M+127.3% | $11.0M+173.3% | -$15.0M-350.0% | $6.0M+101.4% | -$434.0M |
| Net income before allocation to noncontrolling interests | $7.81B-3.1% | $8.06B+273.6% | $2.16B-93.1% | $31.41B+42.6% | $22.02B |
| Less: Net income attributable to noncontrolling interests | $41.0M+32.3% | $31.0M-20.5% | $39.0M+11.4% | $35.0M-22.2% | $45.0M |
| Net income attributable to Pfizer Inc. common shareholders | $7.77B-3.2% | $8.03B+279.0% | $2.12B-93.2% | $31.37B+42.7% | $21.98B |
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | $1.4M-3.5% | $1.4M+281.1% | $370K-93.2% | $5.5M+39.2% | $3.9M |
| Discontinued operations––net of tax (in dollars per share) | $0 | $0 | $0 | $0+100.0% | -$80K |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | $1.4M-3.5% | $1.4M+281.1% | $370K-93.2% | $5.5M+42.1% | $3.9M |
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | $1.4M-3.5% | $1.4M+281.1% | $370K-93.2% | $5.5M+39.2% | $3.9M |
| Discontinued operations––net of tax (in dollars per share) | $0 | $0 | $0 | $0+100.0% | -$80K |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | $1.4M-3.5% | $1.4M+281.1% | $370K-93.2% | $5.5M+42.1% | $3.9M |
| Weighted-average shares––basic (in shares) | $5.68B+0.3% | $5.66B+0.4% | $5.64B+0.6% | $5.61B | — |
| Weighted-average shares––diluted (in shares) | $5.71B+0.2% | $5.70B-0.2% | $5.71B-0.4% | $5.73B | — |
| Product [Member] | |||||
| Revenues | $1.65B+16.0% | $1.42B+34.5% | $1.06B+25.2% | $845.0M | — |
| Royalty [Member] | |||||
| Revenues | $1.65B+16.0% | $1.42B+34.5% | $1.06B+25.2% | $845.0M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell
Morgan Stanley Maintains Pfizer (PFE) at Equal Weight, Highlights Patent Concerns
Pfizer (PFE) Among Best Medical Stocks Under $30 to Invest In?
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%